Thursday, August 20

Browsing: CML

Support

FDA Issues Another CRL for Amorphous Dasatinib Receives in CML and ALL

By NewsCancerAugust 20, 20260

The FDA has issued a new complete response letter (CRL) to Xspray Pharma for Dasynoc, an amorphous formulation of dasatinib,…

Diagnosis

Optimizing Frontline Selection and Treatment-Free Remission in CML

By NewsCancerJuly 1, 20260

Once considered a terminal diagnosis, chronic myeloid leukemia (CML) in chronic phase has been fundamentally rewritten as a highly manageable…

Survivors

Asciminib May Offer Longer, Better Life in Frontline CML Care

By NewsCancerJune 10, 20260

The 144-week analysis of findings from the phase 3 ASC4FIRST trial (NCT04971226) presented at the 2026 American Society of Clinical…

Survivors

TERN-701 Earns FDA Breakthrough Therapy Designation in Ph+ CML

By NewsCancerApril 27, 20260

The FDA has granted breakthrough therapy designation to the investigational BCR::ABL1 inhibitor TERN-701 as a treatment for adults with Philadelphia…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.